ABVC BioPharma, Inc.

ABVC · NASDAQ

ABVC looks like a tiny biotech, a licensing company, a CDMO, and a Taiwan real-asset story in the same filing. The first proof gate is whether cash, controls, and partners can catch up to the size of the pipeline.

Follow Add to Watchlist Ask Question

NASDAQ ABVC Coverage Bootstrap Biotechnology Botanical Drugs Ophthalmology

Latest ReportMay 13, 2026ABVC BioPharma: zero revenue, $21M of assets, and a pipeline too wide for its cash balanceView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.